Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide with or without pegylated interferon alfa-2a in chronic hepatitis delta
2019-001485-15Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bulevirtide and peginterferon alfa-2a in hepatitis D (HDV) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Sustained virological response 24. Started Jul 2019; status: completed.
02
Drugs
bulevirtidepeginterferon alfa-2a
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2019-001485-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001485-15.